Expand all sections

Lesinurad / allopurinol

Duzallo

Extended indication Hyperuricaemia in patients with gout
Therapeutic value No judgement

Product

Active substance Lesinurad / allopurinol
Domain Chronic immune diseases
Main indication Other chronic immune diseases
Extended indication Hyperuricaemia in patients with gout
Proprietary name Duzallo
Manufacturer Grunenthal
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date August 2017
Expected Registration June 2018
Orphan drug No

Therapeutic value

Therapeutic value No judgement
Frequency of administration 1 times a day
Dosage per administration 200/200 mg

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Cost 3,000.00 - 5,000.00
References GoodRx.com
Additional remarks Dit betreft een combinatietherapie, prijs zal wel iets omhoog gaan maar naar verwachting niet veel t.o.v. monotherapie. Prijs in de VS ongeveer $400 voor 30 tabletten 200/200 mg. Dat komt dus neer op ongeveer $4.800 op jaarbasis.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.